Compare · AZN vs PCSA
AZN vs PCSA
Side-by-side comparison of AstraZeneca PLC (AZN) and Processa Pharmaceuticals Inc. (PCSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and PCSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $554.26B, about 96429.0x PCSA ($5.7M).
- Over the past year, AZN is down 5.0% and PCSA is down 68.1% - AZN leads by 63.0 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 10 for PCSA).
- AZN has more recent analyst coverage (25 ratings vs 3 for PCSA).
- Company
- AstraZeneca PLC
- Processa Pharmaceuticals Inc.
- Price
- $178.80+0.92%
- $2.10-7.28%
- Market cap
- $554.26B
- $5.7M
- 1M return
- -1.56%
- -30.00%
- 1Y return
- -5.04%
- -68.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 15
- 10
- Recent ratings
- 25
- 3
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Processa Pharmaceuticals Inc.
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
Latest AZN
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,263 units (SEC Form 4)
- SEC Form 6-K filed by AstraZeneca PLC
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
Latest PCSA
- Pres. Research & Development Young David bought $4,589 worth of shares (2,067 units at $2.22), increasing direct ownership by 12% to 19,198 units (SEC Form 4)
- Chief Financial Officer Skibsted Russell bought $5,892 worth of shares (2,654 units at $2.22), increasing direct ownership by 25% to 13,412 units (SEC Form 4)
- Chief Executive Officer Ng George K bought $5,472 worth of shares (2,465 units at $2.22), increasing direct ownership by 25% to 12,435 units (SEC Form 4)
- Chief Business - Strategy Off Lin Patrick bought $4,065 worth of shares (1,831 units at $2.22), increasing direct ownership by 20% to 11,007 units (SEC Form 4)
- Chief Administrative Officer Guy Wendy bought $4,702 worth of shares (2,118 units at $2.22), increasing direct ownership by 22% to 11,958 units (SEC Form 4)
- Pres. Research & Development Young David bought $4,590 worth of shares (1,786 units at $2.57), increasing direct ownership by 12% to 17,131 units (SEC Form 4)
- Chief Financial Officer Skibsted Russell bought $5,890 worth of shares (2,292 units at $2.57), increasing direct ownership by 27% to 10,758 units (SEC Form 4)
- Chief Executive Officer Ng George K bought $5,472 worth of shares (2,129 units at $2.57), increasing direct ownership by 27% to 9,970 units (SEC Form 4)
- Chief Business - Strategy Off Lin Patrick bought $4,066 worth of shares (1,582 units at $2.57), increasing direct ownership by 21% to 9,176 units (SEC Form 4)
- Chief Administrative Officer Guy Wendy bought $4,701 worth of shares (1,829 units at $2.57), increasing direct ownership by 23% to 9,840 units (SEC Form 4)